Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 9% After Analyst Upgrade

Tandem Diabetes Care, Inc. (NASDAQ:TNDM)’s share price was up 9% during trading on Monday after Lake Street Capital upgraded the stock from a hold rating to a buy rating. Lake Street Capital now has a $50.00 price target on the stock. Tandem Diabetes Care traded as high as $27.92 and last traded at $26.7820. Approximately 857,729 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 1,572,325 shares. The stock had previously closed at $24.57.

Other analysts also recently issued research reports about the company. TD Cowen started coverage on Tandem Diabetes Care in a research report on Tuesday, January 27th. They issued a “buy” rating and a $25.00 target price on the stock. Piper Sandler restated a “neutral” rating and issued a $21.00 price target (up from $14.00) on shares of Tandem Diabetes Care in a research note on Friday. Morgan Stanley set a $23.00 price objective on Tandem Diabetes Care and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Citigroup raised their target price on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Finally, Stifel Nicolaus upped their price target on shares of Tandem Diabetes Care from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tandem Diabetes Care has an average rating of “Hold” and a consensus target price of $28.00.

Trending Headlines about Tandem Diabetes Care

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Lake Street upgraded Tandem, signaling increased analyst confidence in the company’s outlook, which can help investor sentiment. Lake Street upgrades Tandem Diabetes Care (TNDM)
• Positive Sentiment: Analysts and coverage note strong Q4 execution (revenue beat and improving metrics) and a PayGo transition narrative that supports medium‑term growth prospects. This underpins fundamental reasons to hold the stock. Tandem Diabetes Care: Strong Q4 Execution Amid A PayGo Transition
• Positive Sentiment: Truist reaffirmed a “hold” and nudged its price target higher to $27, a modest vote of confidence from a major analyst that may temper downside. Truist hold rating reaffirmed
• Neutral Sentiment: Some outlets show mixed target movement — an article notes a price target moved to $22 (raised from an earlier level), which is still below the current market price and creates mixed signals for investors. Price Target Raised to $22
• Negative Sentiment: The company announced a proposed private placement of $200M aggregate principal of convertible senior notes due 2032 — the financing can extend runway but raises near‑term dilution and convertible overhang concerns that likely pressured the stock. Business Wire: Proposed Private Placement of Convertible Notes
• Negative Sentiment: Market reports show the stock fell on the convertible offering and coverage notes that at least one institutional fund (Brown Capital Management Small Company Fund) sold TNDM — indicating some institutional trimming and contributing to the down‑move. Tandem stock falls on $200M convertible debt offering

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its stake in Tandem Diabetes Care by 54.0% in the second quarter. Acadian Asset Management LLC now owns 358,516 shares of the medical device company’s stock valued at $6,676,000 after purchasing an additional 125,644 shares in the last quarter. Sector Gamma AS grew its stake in Tandem Diabetes Care by 28.0% during the third quarter. Sector Gamma AS now owns 269,542 shares of the medical device company’s stock worth $3,272,000 after buying an additional 59,019 shares in the last quarter. Champlain Investment Partners LLC increased its holdings in Tandem Diabetes Care by 6.3% in the 2nd quarter. Champlain Investment Partners LLC now owns 1,455,123 shares of the medical device company’s stock valued at $27,123,000 after buying an additional 86,235 shares during the period. Dynamic Technology Lab Private Ltd raised its position in shares of Tandem Diabetes Care by 122.2% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 26,143 shares of the medical device company’s stock valued at $488,000 after buying an additional 14,377 shares in the last quarter. Finally, Aberdeen Group plc lifted its holdings in shares of Tandem Diabetes Care by 67.9% during the 3rd quarter. Aberdeen Group plc now owns 598,096 shares of the medical device company’s stock worth $7,261,000 after acquiring an additional 241,878 shares during the period.

Tandem Diabetes Care Stock Performance

The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55. The company has a market cap of $1.84 billion, a P/E ratio of -8.76 and a beta of 1.68. The stock’s fifty day moving average price is $21.12 and its two-hundred day moving average price is $17.27.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, February 19th. The medical device company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.04. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The business had revenue of $290.38 million during the quarter, compared to the consensus estimate of $277.14 million. During the same period in the previous year, the business earned $0.01 earnings per share. The company’s revenue was up 15.1% on a year-over-year basis. As a group, equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.